Evidence map›Paper›PMID 42656863›Full record

ArticleFrontiers in pharmacology2026

Absorption, distribution, metabolism, and excretion of [

Sufeng Zhou, Yuping Wu, Wei Liu, Chen Zhou, Lijun Xie, Quankun Zhuang, Lu Wang, Juan Chen, Bei Zhu, Chen Zhang and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Sufeng ZhouPhase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Yuping WuPhase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Wei LiuNuclear Medicine Department, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Chen ZhouPhase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Lijun XiePhase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Quankun ZhuangPhase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Lu WangPhase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Juan ChenPhase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Bei ZhuPhase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Chen ZhangNuclear Medicine Department, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.
Xiaomeng ZhangNanjing Sanhome Pharmaceutical Co., Ltd., Nanjing, China.
Feng ShaoPhase I Clinical Trial Unit, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: SH-1028 is an irreversible third-generation epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) developed for treating locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring Methods: This integrated preclinical and clinical investigation comprised a radiolabeled mass balance study with quantitative whole-body autoradiography (QWBA) in rats, followed by a human mass balance study of [ Results: Following a single oral dose of [ Conclusion: SH-1028 was well tolerated in subjects after a single oral administration of 200 mg containing 3.26 MBq (88 μCi) of [

Indexed as

mass balancemetabolismNSCLCQWBASH-1028

Identifiers

PMID42656863
PMCPMC13506953

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.